Showing results (851-860 of 1,840) with videos related to

Sort By:
Pageof 184
ESMO Open|July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisS Camera, A Vogel, M Rimini, et al.
ESMO Open|July 6, 2026
Artificial intelligence-based prediction of claudin 18.2 expression and immune phenotype from routine histology to guide treatment decisions in patients with gastric cancerH-D Kim, S Shin, W Hwang, et al.
ESMO Open|July 8, 2026
A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)S J Shin, J L Lee, T Powles, et al.
ESMO Open|July 10, 2026
First-in-human phase I study of hypoxia-targeting 64Cu-ATSM radioligand therapy in patients with malignant brain tumors (STAR-64)H Kurihara, Y Narita, K Ito, et al.
ESMO Open|June 26, 2026
Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinomaR Ibusuki, E Iwama, A Shimauchi, et al.
ESMO Open|July 23, 2026
Somatic BRCA alterations in breast cancer are associated with distinct biological and clinical patterns according to germline BRCA statusM Oshi, K Kawashima, M Sugimori, et al.
ESMO Open|August 12, 2026
Advancing breast cancer clinical management through technological innovation: the potential role of artificial intelligence and integrated care modelsA Toss, L Bellardita, A Botticelli, et al.
ESMO Open|August 14, 2026
Time-dependent prognostic impact of tumor grade in stage I-III breast cancersM Mariani, M Ochocki, G Bianchini, et al.
ESMO Open|August 25, 2026
Asia-Pacific analysis of ESMO study on availability, out-of-pocket costs (OPC) and accessibility of antineoplastic medicinesA N M Wong, P Franco, H S Sheikh, et al.
ESMO Open|September 3, 2026
Longitudinal ctDNA tracking in early and recurrent breast cancer using an ultrasensitive structural variant-based assay: an extended analysis from the TRACER studyM J Elliott, J Roh, T Bird, et al.
Pageof 184